



## **Safinamide data to be presented at World Congress on Parkinson's disease and related disorders in Shanghai**

**Milan, Italy, December 13, 2011** – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today that new data on safinamide will be presented at the XIX World Congress on Parkinson's Disease and Related Disorders (PDRD), December 11-14, 2011, in the Shanghai International Convention Center, Shanghai, China. Safinamide is currently being assessed in Phase III trials as add-on treatment to dopamine agonist or levodopa in early to late stage Parkinson's disease (PD).

“Newron is very excited about the results to be presented at the World Congress and we expect that results of the ongoing phase III trials soon will further substantiate the emerging therapeutic profile of safinamide,” said Dr. Ravi Anand, Newron's Chief Medical Officer.

The following abstracts have been accepted for presentation at the XIX World Congress:

### **First 2-year, placebo-controlled study in Parkinson's disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia**

**Presentation Date:** Tuesday, December 13, 2011

**Session Number:** P005 Poster Session – Therapeutic Interventions

**Poster Presentation Time:** 8:00 AM – 6:00 PM (Present during breaks)

### **Two-year, placebo-controlled safety and tolerability data for safinamide as add-on to levodopa in patients with Parkinson's disease (PD)**

**Presentation Date:** Tuesday, December 13, 2011

**Session Number:** P005 Poster Session – Therapeutic Interventions

**Poster Presentation Time:** 8:00 AM – 6:00 PM (Present during breaks)

### **Long-term efficacy of safinamide as add-on to levodopa in Parkinson's disease (PD) using an 'on' and 'on-off' treatment analysis**

**Presentation Date:** Tuesday, December 13, 2011

**Session Number:** P005 Poster Session – Therapeutic Interventions

**Poster Presentation Time:** 8:00 AM – 6:00 PM (Present during breaks)

### **Safinamide as add-on to levodopa in Parkinson's disease with motor fluctuations may improve responder rates versus placebo during long-term treatment**

**Presentation Date:** Tuesday, December 13, 2011

**Session Number:** P005 Poster Session – Therapeutic Interventions

**Poster Presentation Time:** 8:00 AM – 6:00 PM (Present during breaks)

### **About safinamide**

Safinamide is an alpha-aminoamide that is currently being developed as an add-on therapy to dopamine agonists or levodopa in patients with early or late-stage Parkinson's disease. It is believed to have both dopaminergic and non-dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium channel



antagonism and inhibition of glutamate release in vitro. Studies are ongoing to better understand safinamide's actions in patients with Parkinson's disease.

**About Newron Pharmaceuticals**

Newron Pharmaceuticals S.p.A. ([www.newron.com](http://www.newron.com)) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Phase III trials of safinamide are currently ongoing for the treatment of Parkinson's disease (PD). Newron is currently evaluating the further clinical development of ralfinamide for pain and psychiatric diseases. Newron's additional projects are at various stages of preclinical and clinical development, including HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading symbol NWRN.

**For more information, contact:**

Media	Investors and analysts
<p><b>Italy</b>            Luca Benatti - CEO            Phone: +39 02 6103 4 626            E-mail: <a href="mailto:pr@newron.com">pr@newron.com</a></p> <p><b>UK/Global media</b>            Julia Phillips            Financial Dynamics            Phone: +44 (0) 20 7269 7187</p> <p><b>Switzerland</b>            Martin Meier-Pfister            IRF Communications            Phone: +41 43 244 81 40</p>	<p>Stefan Weber - CFO            Phone: +39 02 6103 46 30            E-mail: <a href="mailto:ir@newron.com">ir@newron.com</a></p> <p><b>Pharmaceutical companies</b>            Wolfgang Stoiber            JSB Partners            Phone: +49 177 723 0152</p>

**Important Notices**

This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and



licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.